Oragenics, Inc. to Present at the June 2020 Virtual Summer Investor Summit
June 04 2020 - 8:00AM
Business Wire
Corporate presentation and live webcast
scheduled for June 10, 2020 at 2:10 pm ET
Oragenics, Inc. (NYSE American: OGEN), announced today
that Alan Joslyn, Ph.D., President and CEO of Oragenics, Inc., will
give a virtual corporate presentation at the June 2020 Virtual
Summer Investor Summit taking place online from June 9th to 12th,
2020.
The presentation will be held on Wednesday, June 10, 2020 at
2:10 pm ET, followed by a live Q&A session with registered
investors and other conference attendees. A live webcast of the
presentation will be available here https://www.webcaster4.com/Webcast/Page/2038/35043.
Dr.. Joslyn will be available for one-on-one meetings online as
well. Interested investors may request a meeting time by emailing:
laura@investorsummitgroup.com.
About Oragenics, Inc.
Oragenics, Inc. is focused on the creation of the TerraCoV2
immunization product candidate to combat the novel coronavirus
pandemic and the further development of effective treatments for
novel antibiotics against infectious disease and oral mucositis.
Through Noachis Terra, a wholly-owned subsidiary of Oragenics, the
Company is dedicated to the development and commercialization of a
vaccine candidate providing specific immunity from the novel
coronavirus, SARS-CoV-2, which causes COVID-19. The TerraCoV2
immunization leverages coronavirus spike protein research conducted
by the National Institute of Health, which issued a worldwide,
nonexclusive intellectual property license to Noachis Terra. In
addition, Oragenics also has two exclusive worldwide channel
collaborations, one with Precigen, Inc.’s subsidiaries relating to
the treatment of oral mucositis and the other with ILH Holdings,
Inc., relating to the development of novel antibiotics.
For more information about Oragenics, please visit
www.oragenics.com.
Safe Harbor Statement
Under the Private Securities Litigation Reform Act of 1995: This
release includes forward-looking statements that reflect
management’s current views with respect to future events and
performance. These forward-looking statements are based on
management’s beliefs and assumptions and information currently
available. The words “believe,” “expect,” “anticipate,” “intend,”
“estimate,” “project” and similar expressions that do not relate
solely to historical matters identify forward-looking statements.
Investors should be cautious in relying on forward-looking
statements because they are subject to a variety of risks,
uncertainties, and other factors that could cause actual results to
differ materially from those expressed in any such forward-looking
statements. These factors include, but are not limited to, risks
and uncertainties described in our filings with the U.S. Securities
and Exchange Commission. Oragenics assumes no responsibility to
update any forward-looking statements contained in this press
release or with respect to the matters described herein.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200604005242/en/
Corporate: Michael Sullivan, 813-286-7900 Chief Financial
Officer msullivan@oragenics.com
or
Investors: John Marco Managing Director CORE IR
516-222-2560 johnm@coreir.com
Media: Jules Abraham CORE IR 917-885-7378
julesa@coreir.com
Oragenics (AMEX:OGEN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Oragenics (AMEX:OGEN)
Historical Stock Chart
From Apr 2023 to Apr 2024